Thorough QT StudiesQuestions and Quandaries

被引:0
|
作者
Marek Malik
Christine E. Garnett
Joanne Zhang
机构
[1] St George’s,Division of Cardiac and Vascular Sciences
[2] University of London,Pharmacometrics Staff, Office of Clinical Pharmacology, Center of Drug Evaluation and Research
[3] Food and Drug Administration,Division of Biometrics VI, Office of Biostatistics/Office of Translational Sciences, Center of Drug Evaluation and Research
[4] Food and Drug Administration,undefined
来源
Drug Safety | 2010年 / 33卷
关键词
Moxifloxacin; Class Comparator; Outlier Analysis; Supratherapeutic Dose; Proarrhythmic Risk;
D O I
暂无
中图分类号
学科分类号
摘要
The International Conference on Harmonisation E14 Guidance was successful in largely standardizing the conduct of the so-called thorough QT/QTc studies (TQTS). Nevertheless, there is still a spectrum of frequently encountered problems with details of design, conduct and interpretation of TQTS. Several of these challenges are reviewed here, starting with explaining that the TQTS goal is only to identify drugs for which the proarrhythmic risk might be considered excluded for the purposes of regulatory benefit-risk assessment. Suggestions are made on how to categorize and quantify or exclude proarrhythmic risk if the TQTS is positive. There is a conceptual need for TQTS, and this is discussed, together with reasons why restricted clinical registries cannot prove the absence of proarrhythmic liability of any drug.
引用
收藏
页码:1 / 14
页数:13
相关论文
共 50 条
  • [1] Thorough QT Studies Questions and Quandaries
    Malik, Marek
    Garnett, Christine E.
    Zhang, Joanne
    DRUG SAFETY, 2010, 33 (01) : 1 - 14
  • [2] Drug-induced QT shortening and fibrillation:: "Thorough or not thorough QT, that is the question?''
    Lu, H. R.
    Van Bergen, P.
    Vlaminckx, E.
    Rohrbacher, J.
    Hermans, A.
    Van Ammel, K.
    Towart, R.
    Pugsley, M. K.
    Gallacher, D. J.
    HEART, 2008, 94 (02)
  • [3] A thorough QT study of guanfacine
    Martin, Patrick
    Satin, Lawrence
    Kahn, Robert S.
    Robinson, Antoine
    Corcoran, Mary
    Purkayastha, Jaideep
    Youcha, Sharon
    Ermer, James C.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (04) : 301 - 316
  • [4] Design of the "Thorough QT Study''
    Darpo, B.
    Sager, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (04) : 528 - 529
  • [5] Pharmacogenetic issues in thorough QT trials
    Judson, Richard S.
    Salisbury, Benjamin A.
    Reed, Carol R.
    Ackerman, Michael J.
    MOLECULAR DIAGNOSIS & THERAPY, 2006, 10 (03) : 153 - 162
  • [6] Response to "Design of the 'Thorough QT Study'"
    Morganroth, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (04) : 529 - 530
  • [7] Pharmacogenetic Issues in Thorough QT Trials
    Richard S. Judson
    Benjamin A. Salisbury
    Carol R. Reed
    Michael J. Ackerman
    Molecular Diagnosis & Therapy, 2006, 10 : 153 - 162
  • [8] Robust Inference in Thorough QT Studies
    Dosne, A. G.
    Bergstrand, M.
    Karlsson, M. O.
    Renard, D.
    Heimann, G.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S59 - S59
  • [9] Weaning off Thorough QT Studies
    Mehanna, Mai
    van der Graaf, Piet H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (01) : 11 - 13
  • [10] Practice and challenges of thorough QT studies
    Stockbridge, Norman
    Zhang, Joanne
    Garnett, Christine
    Malik, Marek
    JOURNAL OF ELECTROCARDIOLOGY, 2012, 45 (06) : 582 - 587